{"title":"Preeclampsia risk factors in French Guiana: a great heterogeneity among populations and geographic areas.","authors":"Malika Leneuve-Dorilas, Fabrice Quet, Stéphanie Bernard, Lindsay Osei, Alphonse Louis, Marie-Noella Capé, Dominique Dotou, Anne-Christèle Dzierzek, Narcisse Elenga, Mathieu Nacher","doi":"10.1080/10641955.2025.2484019","DOIUrl":"10.1080/10641955.2025.2484019","url":null,"abstract":"<p><strong>Background: </strong>French Guiana is France's largest overseas territory, accounting for 1/6th of mainland France. French Guiana has the highest fertility rate in France and Latin America. However, infant mortality, especially neonatal mortality, remains 2.6 times higher than in mainland France. Preeclampsia was found to be the most important pregnancy-related condition contributing to preterm birth in the primary analysis of risk factors for preterm birth in French Guiana.</p><p><strong>Methods: </strong>Therefore, by analyzing the <i>Registre des Issues de Grossesse de Guyane</i> (RIGI), we sought to better describe this condition and understand its risk factors in our area. A retrospective and comparative study was conducted using 2014-2020 data from the RIGI, which describes 53,522 viable births (≥22 weeks of amenorrhea) in all four perinatal facilities in French Guiana. The RIGI is performed by midwives after patients' delivery. It records data up to two hours postpartum.</p><p><strong>Results: </strong>During the study 12.9% of children were born preterm at less than 37 WA (weeks of amenorrhea). 4.5% of the study population had preeclampsia, of which almost half, 49.5%, were expected to deliver prematurely. The Afro-Caribbean population has a higher risk of preeclampsia than the white population, more than double that of the caucasians. Despite adjustment for place of birth, there are spatial heterogeneities in preeclampsia, with an increased risk for residents of towns in western French Guiana.</p><p><strong>Conclusion: </strong>In conclusion, preeclampsia is a major cause of preterm birth and morbidity in French Guiana. The great heterogeneity between populations and geographical areas requires specific blood tests such as angiogenic balance or still heavy metal assays.</p>","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2484019"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hypertension in PregnancyPub Date : 2025-12-01Epub Date: 2024-12-27DOI: 10.1080/10641955.2024.2445556
Dinara Afrose, Sofía Alfonso-Sánchez, Lana McClements
{"title":"Targeting oxidative stress in preeclampsia.","authors":"Dinara Afrose, Sofía Alfonso-Sánchez, Lana McClements","doi":"10.1080/10641955.2024.2445556","DOIUrl":"10.1080/10641955.2024.2445556","url":null,"abstract":"<p><p>Preeclampsia is a complex condition characterized by elevated blood pressure and organ damage involving kidneys or liver, resulting in significant morbidity and mortality for both the mother and the fetus. Increasing evidence suggests that oxidative stress, often caused by mitochondrial dysfunction within fetal trophoblast cells may play a major role in the development and progression of preeclampsia. Oxidative stress occurs as a result of an imbalance between the production of reactive oxygen species (ROS) and the capacity of antioxidant defenses, which can lead to placental cellular damage and endothelial cell dysfunction. Targeting oxidative stress appears to be a promising therapeutic approach that has the potential to improve both short- and long-term maternal and fetal outcomes, thus reducing the global burden of preeclampsia. The purpose of this review is to provide a comprehensive account of the mechanisms of oxidative stress in preeclampsia. Furthermore, it also examines potential interventions for reducing oxidative stress in preeclampsia, including natural antioxidant supplements, lifestyle modifications, mitochondrial targeting antioxidants, and pharmacological agents.A better understanding of the mechanism of action of proposed therapeutic strategies targeting oxidative stress is essential for the identification of companion biomarkers and personalized medicine approaches for the development of effective treatments of preeclampsia.</p>","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2445556"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hypertension in PregnancyPub Date : 2025-12-01Epub Date: 2025-06-30DOI: 10.1080/10641955.2025.2524327
Şebnem Karagün, Hamza Yıldız, Yusuf Dal, Sefanur Gamze Karaca, Ahmet Zeki Nessar, Mürşide Çevikoğlu Kıllı, Ayhan Coşkun
{"title":"Predictive value of 24-hour urine protein levels for adverse maternal and perinatal outcomes in hypertensive pregnancies.","authors":"Şebnem Karagün, Hamza Yıldız, Yusuf Dal, Sefanur Gamze Karaca, Ahmet Zeki Nessar, Mürşide Çevikoğlu Kıllı, Ayhan Coşkun","doi":"10.1080/10641955.2025.2524327","DOIUrl":"https://doi.org/10.1080/10641955.2025.2524327","url":null,"abstract":"<p><strong>Background: </strong>Proteinuria is a widely used biomarker for risk stratification in hypertensive pregnancies, with potential predictive value for adverse maternal and perinatal outcomes. This study evaluated the predictive value of 24-hour urine protein levels for adverse maternal and perinatal outcomes in hypertensive pregnancies.</p><p><strong>Methods: </strong>A retrospective cohort of 213 pregnant women with hypertension was categorized into four groups based on proteinuria severity: <300 mg (<i>n</i> = 147), 300-500 mg (<i>n</i> = 22), 500-2000 mg (<i>n</i> = 25), and > 2000 mg (<i>n</i> = 19).</p><p><strong>Methods: </strong>Higher proteinuria levels were significantly associated with increased rates of oligohydramnios (<i>p</i> = 0.001) and fetal growth restriction (FGR; <i>p</i> = 0.005), particularly in the > 2000 mg group (44.0% and 68.4%, respectively). Gestational age at delivery decreased with worsening proteinuria (<i>p</i> < 0.001), with the lowest mean age (32.84 ± 3.82 weeks) in the > 2000 mg group. Postpartum hospital stays were prolonged in chronic hypertension (<i>p</i> = 0.002) and severe proteinuria groups (<i>p</i> = 0.007). ROC analysis identified a 24-hour urine protein cutoff of 135 mg (AUC: 0.635, <i>p</i> = 0.001) for predicting fetal distress. The > 2000 mg group had universal magnesium sulfate use, earlier deliveries, and higher FGR rates. Chronic hypertension correlated with longer postpartum stays (<i>p</i> = 0.002) and higher postpartum renal disease (<i>p</i> = 0.040).</p><p><strong>Conclusion: </strong>These findings underscore proteinuria as a prognostic marker for adverse outcomes, supporting its role in risk stratification for hypertensive pregnancies. Future research should validate thresholds and explore targeted interventions.</p>","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2524327"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Causal associations of metabolic dysfunction-associated steatotic liver disease with gestational hypertension and preeclampsia: a two-sample Mendelian randomization study.","authors":"Lu Zhang, Liang Fang, Jiahua Zou, Dong Zhou, Haonan Xie, Aihua Chen, Qingming Wu","doi":"10.1080/10641955.2024.2441862","DOIUrl":"https://doi.org/10.1080/10641955.2024.2441862","url":null,"abstract":"<p><strong>Background: </strong>Hypertensive disorders of pregnancy (HDPs), which include gestational hypertension (GH) and preeclampsia (PE), are the primary causes of maternal morbidity and mortality worldwide. Recent studies have found a correlation between metabolic dysfunction-associated steatotic liver disease (MASLD) and HDPs, but the causality of this association remains to be identified. Therefore, this study aims to evaluate the causal relationship between MASLD and HDPs through Mendelian randomization (MR) analysis.</p><p><strong>Methods: </strong>The summary statistics from genome-wide association studies were employed to conduct a two-sample MR analysis. Five complementary MR methods, including inverse variance weighting (IVW), MR-Egger, weighted median, simple mode and weighted mode were performed to assess the causality of MASLD on GH and PE. Furthermore, we conducted various sensitivity analyses to ensure the stability and reliability of the results.</p><p><strong>Results: </strong>Genetically predicted MASLD significantly increased the risk of GH (IVW: OR = 1.138, 95% CI: 1.062-1.220, <i>p</i> < 0.001), while there was little evidence of a causal relationship between MASLD and PE (IVW: OR = 0.980, 95% CI: 0.910-1.056, <i>p</i> = 0.594). The sensitivity analyses indicated no presence of heterogeneity and horizontal pleiotropy.</p><p><strong>Conclusion: </strong>This MR study provided evidence supporting the causal effect of MASLD on GH. Our findings underscore the significance of providing more intensive prenatal care and early intervention for pregnant women with MASLD to prevent potential adverse obstetric outcomes.</p>","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2441862"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Placental ischemia during pregnancy induces hypertension, cerebral inflammation, and oxidative stress in dams postpartum.","authors":"Savanna Smith, Jonna Smith, Kylie Jones, Angie Castillo, Natalia Wiemann, Ahfiya Howard, Mark Cunningham","doi":"10.1080/10641955.2025.2454597","DOIUrl":"10.1080/10641955.2025.2454597","url":null,"abstract":"<p><strong>Background: </strong>Preeclampsia (PE) is characterized as de novo hypertension (HTN) with end-organ damage, especially in the brain. PE is hypothesized to be caused by placental ischemia. PE affects ~5-8% of USA pregnancies and increases the risk for HTN and cerebrovascular diseases (CVD) later in life. We hypothesize that blood pressure (BP), cerebral oxidative stress, and cerebral inflammation will increase in postpartum (PP) placental ischemic dams.</p><p><strong>Methods: </strong>Placental ischemia was induced in pregnant Sprague Dawley dams, utilizing reduced uterine perfusion pressure (RUPP) surgery. At 6 weeks PP (~3 human years), BP was measured via carotid catheterization, and cerebral oxidative stress and inflammation were assessed via ELISAs, biochemical assays, and Western blots.</p><p><strong>Results: </strong>BP, cerebral pro-inflammatory cytokines (TNF-α and IL-6), and GFAP (a marker of astrocyte activity) were increased in PP RUPP dams. Cerebral hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) was also increased in PP RUPP dams, and had a strong correlation with PP RUPP BP, proinflammatory cytokines (TNF- α and IL-6), and GFAP astrocyte activation.</p><p><strong>Conclusion: </strong>PP RUPP dams have increased BP, cerebral oxidative stress, and cerebral inflammation at 6 weeks postpartum. These changes in cerebral inflammation and oxidative stress may contribute to the pathology and development of HTN and CVDs in postpartum dams.</p>","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2454597"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hypertension in PregnancyPub Date : 2025-12-01Epub Date: 2025-05-06DOI: 10.1080/10641955.2025.2496570
{"title":"Statement of Retraction: Carbetocin versus oxytocin for prevention of postpartum hemorrhage in hypertensive women undergoing elective cesarean section.","authors":"","doi":"10.1080/10641955.2025.2496570","DOIUrl":"https://doi.org/10.1080/10641955.2025.2496570","url":null,"abstract":"","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2496570"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hypertension in PregnancyPub Date : 2025-12-01Epub Date: 2025-07-01DOI: 10.1080/10641955.2025.2524324
Xolani B Mbongozi, Stuart D R Galloway, Angus Hunter, Mirabel Nanjoh, Charles B Businge
{"title":"Elevated central blood pressure, NT-proBNP and hs-cTnI in women with maternal complications of hypertensive disorders of pregnancy.","authors":"Xolani B Mbongozi, Stuart D R Galloway, Angus Hunter, Mirabel Nanjoh, Charles B Businge","doi":"10.1080/10641955.2025.2524324","DOIUrl":"https://doi.org/10.1080/10641955.2025.2524324","url":null,"abstract":"<p><strong>Objective: </strong>The main objective of the study was to compare the levels of CBP and these cardiac biomarkers in women with maternal complications of hypertensive disorders of pregnancy (HDP).</p><p><strong>Methods: </strong>This was a cross-sectional study that enrolled 270 women with HDP and 270 normotensive pregnant controls. Data on basic characteristics and incidence of maternal complications were collected among the two groups. Additionally, information on cardiac biomarkers and CBP was gathered from the women with HDP, to compare the levels of these biomarkers with maternal complications experience by this group.</p><p><strong>Results: </strong>Non-hypertensive controls were significantly older than hypertensive cases and had a higher median gestational age at recruitment compared to hypertensive cases The median levels of CBP and cardiac biomarkers were significantly higher among hypertensive participants with maternal complications (<i>n</i> = 107/270) than those without complications (<i>n</i> = 163/270). Specifically, central systolic blood pressure (CSBP) was 133 (120-142) mmHg vs 128 (109-129) mmHg (<i>p</i> = 0.033) and central diastolic blood pressure (CDBP) was 75 (62-86) mmHg vs 69 (56-73) mmHg (<i>p</i> < 0.01), while NT-proBNP was 446 (145-1126) vs. 57 (21-167)) pg.ml<sup>-1</sup>; <i>p</i> < 0.0001, and hs-cTnI was 12 (7-35) ng.L<sup>-1</sup> compared to 8 (3-8) ng.L<sup>-1</sup>; <i>p</i> < 0.0001, in cases v. controls, respectively.</p><p><strong>Conclusion: </strong>In conclusion, the study found that pregnant hypertensive women with maternal complications had significantly higher median values of CSBP and CDBP, NT-proBNP, and hs-cTnI in compared to those without complications. These findings suggest that measuring these vital signs and cardiac biomarkers in hypertensive pregnancies might be helpful for screening and monitoring maternal complications.</p>","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2524324"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hypertension in PregnancyPub Date : 2025-12-01Epub Date: 2025-07-16DOI: 10.1080/10641955.2025.2527138
Yihua Ni, Liying Zhong, Huale Zhang, Xiaoyan Xiu
{"title":"Differences in hematocrit-to-plasma albumin ratio as a predictor of severe maternal morbidity in hypertensive disorders of pregnancy: a retrospective cohort study.","authors":"Yihua Ni, Liying Zhong, Huale Zhang, Xiaoyan Xiu","doi":"10.1080/10641955.2025.2527138","DOIUrl":"https://doi.org/10.1080/10641955.2025.2527138","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the hematocrit-to-albumin ratio (HCT-ALB) as a predictor of severe maternal morbidity (SMM) in pregnancies complicated with hypertensive disorders of pregnancy (HDP).</p><p><strong>Areas covered: </strong>This retrospective cohort study analyzed clinical data of 794 women with singleton pregnancies diagnosed with HDP at Fujian Provincial Maternal and Child Health Hospital from 1 January 2016, to 31 December 2018. HCT-ALB was a primary outcome of interest. Maternal outcomes, including SMM events (e.g. ICU admission or transfusion), were recorded. Multivariate logistic regression, threshold effect analysis, and receiver operating characteristic (ROC) curve evaluation were used to assess the predictive value of HCT-ALB and other clinical indicators. HCT-ALB was identified as an independent risk factor for SMM, with an inflection point at 6.9, beyond which the risk increased significantly. ROC curve analysis demonstrated that HCT-ALB had an area under the curve (AUC) of 0.717, outperforming other single biomarkers. When combined with gestational age, platelet index, systolic blood pressure and maternal age, the AUC improved to 0.817.</p><p><strong>Expert opinion/commentary: </strong>HCT-ALB is a practical and scalable biomarker for predicting SMM in HDP. Its integration into clinical protocols could improve risk stratification and early intervention. Future studies should validate these findings in multi-ethnic and multi-center populations, incorporating social and economic factors to enhance predictive models and global applicability.</p>","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2527138"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Urine and serum L-type fatty acid-binding protein levels in preeclampsia: a prospective cohort study on maternal deterioration prediction.","authors":"Daisuke Katsura, Shunichiro Tsuji, Shinsuke Tokoro, Ayako Inatomi, Nobuyuki Kita, Takashi Murakami","doi":"10.1080/10641955.2025.2534508","DOIUrl":"https://doi.org/10.1080/10641955.2025.2534508","url":null,"abstract":"<p><strong>Background: </strong>We aimed to examine the association between maternal urine and serum L-type fatty acid-binding protein (L-FABP) levels and preeclampsia (PE) severity and their potential as predictors of maternal and fetal deterioration following PE diagnosis.</p><p><strong>Method: </strong>A prospective cohort of women with singleton pregnancies diagnosed with PE was analyzed. Participants were classified into two groups based on the timing of delivery: PE-delivery (delivery within 1 week of sample collection) and PE-non-delivery (no delivery within 1 week). Urine and serum samples were collected at the time of PE diagnosis, and cases were classified based on the presence of maternal or fetal complications.</p><p><strong>Results: </strong>In total, 53 singleton pregnancies were analyzed and classified into the PE-delivery (n = 32) and PE-non-delivery groups (n = 21). No significant differences in L-FABP levels were observed between severe and non-severe PE cases. However, L-FABP levels were significantly higher in cases of severe PE due to maternal factors. In the PE-delivery group, urine and serum L-FABP levels were significantly elevated in cases requiring delivery within 1 week due to maternal indications compared to the PE-non-delivery group, whereas no such differences were found in cases with fetal indications. Receiver operating characteristic analysis showed strong predictive performance of L-FABP levels for delivery within 1 week due to maternal deterioration, with areas under the curve of 0.892 (urine, cutoff: 12.3 μg/gCr) and 0.795 (serum, cutoff: 1.64 ng/mL).</p><p><strong>Conclusion: </strong>Maternal urine and serum L-FABP levels are closely associated with PE severity due to maternal complications and may serve as reliable biomarkers for imminent maternal deterioration.</p>","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2534508"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hypertension in PregnancyPub Date : 2025-12-01Epub Date: 2025-03-20DOI: 10.1080/10641955.2025.2477933
{"title":"Statement of Retraction.","authors":"","doi":"10.1080/10641955.2025.2477933","DOIUrl":"https://doi.org/10.1080/10641955.2025.2477933","url":null,"abstract":"","PeriodicalId":13054,"journal":{"name":"Hypertension in Pregnancy","volume":"44 1","pages":"2477933"},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}